Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 2Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Esophageal Neoplasms 3Colorectal Neoplasms 2Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Rectal Neoplasms 1Pancreatic carcinoma, familial 1Pancreatic Neoplasms 1Pancreatic Intraductal Neoplasms 1Ovarian Neoplasms 1Liver Neoplasms 1Liver Cirrhosis 1Head and Neck Neoplasms 1Carcinoma, Hepatocellular 1

Interventions

pembrolizumab 29Cetuximab 11Nivolumab 10Fluorouracil 8Cyclophosphamide 8Cisplatin 8Carboplatin 8fludarabine 7atezolizumab 7Blood Specimen Collection 7cemiplimab 6Radiotherapy 6Drug Therapy 6Immune Checkpoint Inhibitors 5Gemcitabine 5Paclitaxel 4Docetaxel 4Capecitabine 4Biopsy 4spartalizumab 3avelumab 3Surveys and Questionnaires 3Pemetrexed 3Oncolytic Virotherapy 3Nicotine 3Magnetic Resonance Spectroscopy 3Irinotecan 3Ipilimumab 3Interleukin-2 3Bortezomib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Head and Neck Neoplasms × Ferrosoferric Oxide × Gastrointestinal × Clear all
NCT01770353 2019-11-27

MM-398 (Nanoliposomal Irinotecan, Nal-IRI) to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to Treatment

Ipsen

Phase 1 Completed
45 enrolled 33 charts
BreastGastrointestinalGynecologicHead & Neck

Head and Neck Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡